15762 Results

People

  1. Hudis
    Hudis
  2. Offit
    Offit
  3. Zelefsky
    Zelefsky
  4. Giralt
    Giralt
  5. Robson
    Robson
  6. Yahalom
    Yahalom
  7. Wolden
    Wolden
  8. Coit
    Coit
  9. Marghoob
    Marghoob
  10. Tuttle
    Tuttle

Groups

  1. Survivorship Research (15762)
  2. Department of Medicine (9201)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5183)
  5. Surgery (5130)
  6. Epidemiology and Biostatistics (3598)
  7. Division of Subspecialty Medicine (3242)
  8. Center for Hematologic Malignancies (2610)
  9. Biostatistics Service (2488)
  10. GSK Faculty (2413)
  1. "Survivorship Research"
Formats
  1. Journal Article (8899)
  2. Meeting Abstract (5192)
  3. Book Section (571)
  4. Review (357)
  5. Editorial (225)
  6. Research Letter (132)
  7. Conference Paper (104)
  8. Correspondence (91)
  9. Guidelines (85)
  10. Miscellaneous (76)
  11. Book Whole (30)
Groups
  1. Survivorship Research (15762)
  2. Department of Medicine (9201)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5183)
  5. Surgery (5130)
  6. Epidemiology and Biostatistics (3598)

More Groups

People
  1. Clifford Hudis (905)
  2. Kenneth Offit (788)
  3. Michael Zelefsky (754)
  4. Sergio Giralt (684)
  5. Mark Robson (676)
  6. Joachim Yahalom (625)

More People

Years
  1. 2025 (231)
  2. 2024 (802)
  3. 2023 (892)
  4. 2022 (906)
  5. 2021 (922)
  6. 2020 (930)

More Years

Publications
  1. Journal of Clinical Oncology (1873)
  2. International Journal of Radiation Oncology, Biology, Physics (908)
  3. Blood (685)
  4. Annals of Surgical Oncology (599)
  5. Cancer Research (333)
  6. Cancer (331)

More Publications

Publishers
  1. Elsevier Inc. (2658)
  2. American Society of Clinical Oncology (2019)
  3. Springer (1542)
  4. Wiley Blackwell (806)
  5. Oxford University Press (787)
  6. American Society of Hematology (748)

More Publishers

Results (15762)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Dugan, U.; Feigin, K.; Patil, S.; Edwards, C.; Norton, L.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Survival analyses from the Women's Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome
    Meeting Abstract

    Chlebowski, R. T.; Blackburn, G. L.; Hoy, M. K.; Thomson, C. A.; Giuliano, A. E.; McAndrew, P.; Hudis, C. A.; Butler, J.; Shapiro, A.; Elashoff, R. M.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Reflex testing of lung adenocarcinomas for EGFR and KRAS mutations: The Memorial Sloan-Kettering experience
    Meeting Abstract

    Zakowski, M. F.; Ladanyi, M.; Rekhtman, N.; Park, B. J.; Finley, D.; Azzoli, C. G.; Riely, G. J.; Rusch, V. W.; Kris, M. G.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Psychosocial functioning in survivors of Hodgkin lymphoma (HL) treated during adulthood
    Meeting Abstract

    Ford, J. S.; Schwartz, J.; McCallen, L. N.; Matasar, M. J.; Butos, J. N.; Riedel, E. R.; Weinstock, D. M.; Oeffinger, K. C.; Straus, D. J.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC)
    Meeting Abstract

    Gennari, A.; Sormani, M.; Bruzzi, P.; Wilcken, N.; Nanni, O.; Fornier, M.; Stockler, M. R.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Prevalence of BRCA1 and BRCA2 mutations in Jewish women with triple negative breast cancer
    Meeting Abstract

    Comen, E. A.; Davids, M.; Kirchhoff, T.; Balistreri, L.; Hansen, J.; Kosarin, K.; Offit, K.; Robson, M. E.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C. T.; Lin, N. U.; Lake, D.; Dickler, M. N.; Modi, S.; Seidman, A. D.; Steingart, R. M.; Norton, L.; Winer, E. P.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Permanent lung implants: How many seeds?
    Meeting Abstract

    Cohen, G. N.; Rosenzweig, K. E.; Zelefsky, M. J.; Alektiar, K. M.; Schupak, K. D.; Yamada, Y.; Zaider, M.
    Brachytherapy (2008)

    Fulltext@MSK | Save
  • Concurrent chemoradiation for locally advanced prostate cancer
    Journal Article

    Kollmeier, M. A.; Cox, B.; Zelefsky, M. J.
    American Journal of Hematology/Oncology (2008)

    Fulltext@MSK | Save
  • Low-risk prostate cancer
    Book Section

    Zelefsky, M. J.; Valicenti, R. K.; Hunt, M.; Perez, C. A.
    In Halperin, E. C.; Perez, C. A.; Brady, L. W. (Eds.) Perez and Brady’s Principles and Practice of Radiation Oncology. 5th ed (2008)

    Fulltext@MSK | Save